This Company Wants to Rewrite the Future of Genetic Disease—Without Crispr Gene Editing
By Megan Molteni,
Wired
| 07. 07. 2020
Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.
CRISPR’S POTENTIAL FOR curing inherited disease has made headlines, including at WIRED, for years. ( Here, here, here, and here.) Finally, at least for one family, the gene-editing technology is turning out to deliver more hope than hype. A year after 34-year-old Victoria Gray received an infusion of billions of Crispr’d cells, NPR reported last week that those cells were still alive and alleviating the complications of her sickle cell disease. Researchers say it’s still too soon to call it a cure. But as the first person with a genetic disorder to be successfully treated with Crispr in the US, it’s a huge milestone. And with dozens more clinical trials currently in progress, Crispr is just getting started.
Yet for all its DNA-snipping precision, Crispr is best at breaking DNA. In Gray’s case, the gene editor built by Crispr Therapeutics intentionally crippled a regulatory gene in her bone marrow cells, boosting production of a dormant, fetal form of hemoglobin, and overcoming a mutation that leads to poor production of the adult form of the oxygen-carrying molecule.... see more
Related Articles
By Fiona Harvey, The Guardian | 01.06.2021
By Jeffrey Mervis, Science | 01.06.2021
Low-income commuters who rely on public transit face many challenges—multiple transfers, long waits, and off-hour travel—that aren’t measured in the usual ridership surveys. Vanessa Frias-Martinez, a computer scientist at the University of Maryland, College Park, wants to ease their commute...
By Sharon Begley, STAT | 01.06.2021
Biologists tend not to discuss experimental results on a handful of cells and a single solitary mouse — too preliminary, too sketchy. David Liu of the Broad Institute therefore had no plans to present such findings, which he’d peeked at...
By Gwen D’Arcangelis, Guest Contributor
| 01.07.2021
Photo by Adrian Lange on Unsplash
Living under the COVID-19 pandemic has justifiably created fear and uncertainty about germs and their evolving contagiousness and lethality. Against the backdrop of the natural evolution of the coronavirus and emerging new strains, many ruminate over further alarming scenarios—from questions about the coronavirus’s possible lab origins, to worry over the possibility of biohackers engineering new pandemic germs. New gene editing technologies like CRISPR make these scenarios all the more frightening, as they...
